Search Result

Results for "

BT474

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (7) AMPK (3) Antibiotic (1) Apoptosis (6) ATM/ATR (1) Autophagy (2) Bacterial (1) Btk (1) Cadherin (1) CDK (1) DNA Alkylator/Crosslinker (1) DNA-PK (1) Drug-Linker Conjugates for ADC (2) EGFR (15) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) Fatty Acid Synthase (FASN) (2) Histone Demethylase (1) HSP (2) MDM-2/p53 (1) Microtubule/Tubulin (1) mTOR (1) Notch (1) PERK (1) PI3K (1) PROTACs (2) Proteasome (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (1) SHP2 (1) Sodium Channel (1) Survivin (1) Toll-like Receptor (TLR) (3) TRP Channel (1) γ-secretase (1)
By Research Areas:	Cancer (41) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (7)

AMPK (3)

Antibiotic (1)

Apoptosis (6)

ATM/ATR (1)

Autophagy (2)

Bacterial (1)

Btk (1)

Cadherin (1)

CDK (1)

DNA Alkylator/Crosslinker (1)

DNA-PK (1)

Drug-Linker Conjugates for ADC (2)

EGFR (15)

Epigenetic Reader Domain (1)

ERK (1)

Estrogen Receptor/ERR (1)

Fatty Acid Synthase (FASN) (2)

Histone Demethylase (1)

HSP (2)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

mTOR (1)

Notch (1)

PERK (1)

PI3K (1)

PROTACs (2)

Proteasome (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Reference Standards (1)

SHP2 (1)

Sodium Channel (1)

Survivin (1)

Toll-like Receptor (TLR) (3)

TRP Channel (1)

γ-secretase (1)

By Research Areas:

Cancer (41)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108931

AG 1406	EGFR	Cancer
AG 1406 (compound M19) is a HER2 inhibitor, with an IC₅₀ of 10.57 μM for HER2 in BT474 cell and >50 μM for EGFR in EGF-3T3 cell .

HY-159852

BBO-10203	PI3K Akt	Cancer
BBO-10203 (Compound 758) binds to the RBD region of PI3Kα, and inhibits the binding of K-, H-, and N-Ras to PI3Kα. BBO-10203 inhibits pAKT with an IC₅₀ < 0.1 pM in BT474 cell .

HY-161781

HVH-2930	HSP EGFR Akt Survivin	Cancer
HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC₅₀ of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice .

HY-169307

BTK-IN-38	Btk	Cancer
BTK-IN-38 (Example 125) is a potent BTK inhibitor. BTK-IN-38 inhibits DOHH2 and BT474 cells proliferation with IC₅₀s of 114 and 340 nM, respectively .

HY-163428

Perzebertinib ZN-A-1041	EGFR	Inflammation/Immunology Cancer
ZN-A-1041 inhibits HER2 in BT474 cell and wt-EGFR in H838 cells, with IC₅₀s of 9.5 nM and 12 μM respectively. ZN-A-1041 can be used for research of cancer and inflammation .

HY-155098

CNBCA	SHP2	Cancer
CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC₅₀ of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study .

HY-160613

EGFR/HER2-IN-11	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-163453

HER2-IN-19	EGFR	Cancer
HER2-IN-19 (Compound 10e) is a potent inhibitor of HER2 and EGFR with IC₅₀ values of 0.87 respectively and 3.5 nM. HER2-IN-19 has potent inhibitory activity against tumor cells, IC₅₀ ^NCI-N87 = 1.63 nM, IC₅₀ ^BT474= 15.17 nM, IC₅₀ ^{BaF3-HER2YVMA} = 1.49 nM .

HY-160899A

Thailanstatin A cyclohexane diamine formic	Drug-Linker Conjugates for ADC	Cancer
Thailanstatin A cyclohexane diamine formic is an analog of Spliceostatin (HY-16466). Thailanstatin A cyclohexane diamine formic inhibits proliferations of cells N87 (IC₅₀ is 0.33 μM), BT474 (IC₅₀ is 0.34 μM), MDA-MB-361-DYT2 (IC₅₀ is 0.88 μM) and MDA-MB-468 (IC₅₀ is 0.27 μM). Thailanstatin A cyclohexane diamine formic is used as a drug-linker conjugate for ADC molecule .

HY-164399

SST0116CL1	HSP EGFR CDK Akt	Cancer
SST0116CL1 is a HSP90 inhibitor (IC₅₀: 0.21 μM). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC₅₀: 0.2 μM). SST0116CL1 has antiproliferative activity and inhibits tumor growth .

HY-P991328

MAb604.107	Notch	Cancer
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .

HY-111551

FT113 3 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC₅₀ of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC₅₀, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .

HY-N3626

Coronalolide	Others	Cancer
Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC₅₀ values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .

HY-W087187

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.

HY-177008

PROTAC HER2 degrader-1	PROTACs EGFR Apoptosis Akt ERK	Cancer
PROTAC HER2 degrader-1 is a highly selective HER2 PROTAC degrader, with a DC₅₀ of 69 nM and a D_max of 96%. PROTAC HER2 degrader-1 inhibits HER2-positive cell proliferation and tumor growth through persistent HER2 degradation and potent inhibition of downstream pathways (AKT and ERK). PROTAC HER2 degrader-1 induces apoptosis in BT-474 cells. PROTAC HER2 degrader-1 can be used for research of HER2-positive cancers. (Pink: HER2 ligand: (HY-177009); Black: Linker; Blue: CRBN ligand: (HY-W023573) .

HY-P10785

Iturin A-2	Bacterial Antibiotic	Infection
Iturin A-2 is a cyclic lipopeptide discovered in B. subtilis and exhibits inhibitory activity against the plant pathogenic fungus P. expansum (MIC = 8 µg/disk). Iturin A-2 is cytotoxic to MCF-7 and BT474 breast cancer cells, as well as HeLa cervical cancer cells, with IC₅₀ values of 66.81, 95.04, and 77.5 µg/mL, respectively. In greenhouse studies, Iturin A-2 at concentrations of 100 and 300 mg/kg Iturin A-2 reduces the lesion area of southern corn leaf blight caused by B. maydis, and in field studies, concentrations of 300 and 500 mg/kg Iturin A-2 reduce the incidence of the disease. Iturin A-2 (12.5 µg/mL) inhibits cell division, but not nuclear division, in isolated fertilized starfish eggs .

HY-164088

DBM-C5-VC-PAB-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DBM-C5-VC-PAB-MMAE (Compound 3a) is a Drug-Linker conjugate for ADC. DBM-C5-VC-PAB-MMAE is composed of a linker C5-VC-PAB with a maleimide group DBM and an ADC toxin MMAE (HY-15162) .

HY-153468

ErSO-TFPy	Sodium Channel TRP Channel	Cancer
ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy exhibits low nanomolar cytotoxicity in ERα+ breast cancer cell lines (IC₅₀ = 5-25 nM) through induction of necrosis. ErSO-TFPy exhbits antitumor efficacy in mouse models .

HY-107226

Crovatin	Others	Cancer
Crovatin, isolated from the stem bark of C. oblongifolius, shows anti-tumor effect .

HY-158649

Fasnall benzenesulfonate	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall benzenesulfonate is the benzenesulfonate salt form of Fasnall (HY-121250). Fasnall benzenesulfonate is the inhibitor for fatty acid synthase (FASN) with IC₅₀ of 3.7 μM. Fasnall benzenesulfonate inhibits the proliferation and induces apoptosis in breast cancer cells. Fasnall benzenesulfonate exhibits antitumor efficacy in mice .

HY-163134

DNA-PK-IN-12	DNA-PK	Cancer
DNA-PK-IN-12 (compound 31t) is an oral active DNA-PK inhibitor with the IC₅₀ of 0.1 nM. DNA-PK-IN-12 inhibits cell growth and Hct116 cell colony formation with the IC₅₀ of 33.28 μM, and shows antitumor activity in vivo .

HY-141478

Antitumor agent-28	ATM/ATR	Cancer
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .

HY-174414

EGFR/HER2-IN-18	EGFR	Cancer
EGFR/HER2-IN-18 is a stable EGFR/HER2 dual inhibitor with IC₅₀ values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer .

HY-176744

HER2-IN-22	EGFR Apoptosis	Cancer
HER2-IN-22 is a potent and selective HER2 inhibitor with an IC₅₀ of 215 μM. HER2-IN-22 possesses killing activity against various tumor cells and can induce cell apoptosis. HER2-IN-22 significantly inhibits tumor growth. HER2-IN-22 can be used in the study for tumors such as HER2+ breast cancer .

HY-100764

YUKA1	Histone Demethylase	Cancer
YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC₅₀ of 2.66 μM. YUKA1 has less inhibitory active on KDM5C (IC₅₀ = 7.12 μM) and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 can increase H3K4me3 levels and inhibit cell proliferation. YUKA1 can be used for the research of cancer, such as lung and breast cancers .

HY-P990248

Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1)	Cadherin EGFR PERK Akt mTOR	Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is an anti-mouse E-Cadherin/CD324 IgG1 monoclonal antibody. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can downregulate the HER signaling axis and PI3K/Akt/mTOR signaling pathway. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can inhibit the proliferation of tumor cells and induce their apoptosis. Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) can be used for researches on cancer and inflammation conditions such as breast cancer, chronic compression injury (CCI) and asthma .

HY-161629

TLR8 agonist 7	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 7 (Compound II-36) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ <250 nM. TLR8 agonist 7 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 7 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 98% .

HY-161630

TLR8 agonist 8	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 8 (Compound II-72) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 8 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 8 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 89% .

HY-161631

TLR8 agonist 9	Toll-like Receptor (TLR)	Cancer
TLR8 agonist 9 (Compound II-77) is an agonist for Toll-like receptor 8 (TLR8) with EC₅₀ of 0.25-1 μM. TLR8 agonist 9 is stable in human and murine plasma, induces secretion of cytokines TNFα, with EC₅₀ <1 μM. TLR8 agonist 9 exhibits antitumor activity in MC38-HER2 xenograft mouse model with a tumor growth inhibition (TGI) rate of 97% .

HY-32721

Neratinib Maximum Cited Publications 21 Publications Verification HKI-272	EGFR	Cancer
Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-32721R

Neratinib (Standard) HKI-272 (Standard)	Reference Standards EGFR	Cancer
Neratinib (Standard) is the analytical standard of Neratinib. This product is intended for research and analytical applications. Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-32721B

Neratinib maleate Maximum Cited Publications 21 Publications Verification HKI-272 maleate	EGFR	Cancer
Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-B2099

Buformin 1-Butylbiguanide	AMPK	Metabolic Disease Cancer
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-13260A

CCT128930 hydrochloride 5 Publications Verification	Akt Autophagy Apoptosis	Cancer
CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC₅₀=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .

HY-B2099AR

Buformin hydrochloride (Standard)	AMPK	Cancer
Buformin (hydrochloride) (Standard) is the analytical standard of Buformin (hydrochloride). This product is intended for research and analytical applications. Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-141890

BAZ1A-IN-1	Epigenetic Reader Domain	Cancer
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K_D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A .

HY-B2099A

Buformin hydrochloride 3 Publications Verification 1-Butylbiguanide hydrochloride	AMPK	Cancer
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-13260

CCT128930 5 Publications Verification	Akt Autophagy Apoptosis	Cancer
CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

HY-103441

JNJ28871063 hydrochloride	EGFR	Cancer
JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive pan-ErbB kinase inhibitor with IC₅₀ values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively. JNJ28871063 hydrochloride inhibits phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2. JNJ28871063 hydrochloride crosses the blood-brain barrier and has antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2 .

HY-135312

AZ'6421	Estrogen Receptor/ERR PROTACs	Cancer
AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer .

HY-U00447

PK11000	MDM-2/p53 DNA Alkylator/Crosslinker	Cancer
PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities .

Cat. No.	Product Name	Target	Research Area